This study compared the efficacy and safety of caspofungin and amphotericin B in treating invasive candidiasis. The trial was designed as a double-blind, randomized controlled trial, enrolling patients with clinical evidence of candida infection from blood or other sites. Patients were stratified by disease severity and neutropenia status and randomly assigned to receive either caspofungin or amphotericin B. The primary outcome measure was the overall response rate after intravenous therapy, adjusted for neutropenic status and APACHE II score. The study found that caspofungin was as effective as amphotericin B in treating invasive candidiasis, with a favorable response rate of 73.4% in the caspofungin group and 61.7% in the amphotericin B group. However, when evaluated in a subgroup of patients meeting prespecified criteria, caspofungin showed superior efficacy, with a favorable response rate of 80.7% compared to 64.9% for amphotericin B. Caspofungin also demonstrated fewer drug-related adverse events, particularly nephrotoxicity and hypokalemia. The study concluded that caspofungin is a safe and effective alternative to amphotericin B for the treatment of invasive candidiasis, especially candidemia.This study compared the efficacy and safety of caspofungin and amphotericin B in treating invasive candidiasis. The trial was designed as a double-blind, randomized controlled trial, enrolling patients with clinical evidence of candida infection from blood or other sites. Patients were stratified by disease severity and neutropenia status and randomly assigned to receive either caspofungin or amphotericin B. The primary outcome measure was the overall response rate after intravenous therapy, adjusted for neutropenic status and APACHE II score. The study found that caspofungin was as effective as amphotericin B in treating invasive candidiasis, with a favorable response rate of 73.4% in the caspofungin group and 61.7% in the amphotericin B group. However, when evaluated in a subgroup of patients meeting prespecified criteria, caspofungin showed superior efficacy, with a favorable response rate of 80.7% compared to 64.9% for amphotericin B. Caspofungin also demonstrated fewer drug-related adverse events, particularly nephrotoxicity and hypokalemia. The study concluded that caspofungin is a safe and effective alternative to amphotericin B for the treatment of invasive candidiasis, especially candidemia.